Press release
Dystrophin Gene Therapy Market to hit US$ 12.00 billion by 2033: Clinical Developments, Next Big Thing in Genetic Medicine
Dystrophin Gene Therapy Market
The treatment showed 122.3% and 31.5% higher expression in patients aged 3-7. RGX-202 targeted the sarcolemma and was well-tolerated with no serious adverse events. More phase 1/2 data will be shared in 2025.
In November 2024, REGENXBIO dosed the first patient in the phase 3 AFFINITY DUCHENNE trial, aiming to submit a BLA by mid-2026.
For example, Elevidys, a groundbreaking AAV vector-based gene therapy for DMD, can cost up to US$ 3.2 million per single dose, ranking it among the most expensive treatments available.
Exon-skipping dominated the therapeutic approach segment with a 57.0% market share in the global dystrophin gene therapy market in 2024.
North America led the dystrophin gene therapy market, holding the largest share of 86.5% in 2024.
United States: Recent Industry Developments
✅ October 2025: Sarepta Therapeutics advanced clinical trials of next-generation dystrophin gene therapies targeting Duchenne Muscular Dystrophy.
✅ September 2025: FDA granted breakthrough therapy designation for novel gene editing approaches improving dystrophin expression.
✅ August 2025: Collaborative research expanded delivery vector technologies for enhanced safety and efficacy in gene therapy.
Japan: Recent Industry Developments
✅ October 2025: Takeda Pharmaceuticals initiated partnerships to develop innovative dystrophin gene therapies tailored for the Japanese population.
✅ September 2025: Academic institutions in Japan focused on CRISPR-based gene editing for muscular dystrophy treatment.
✅ August 2025: Government funding supported translational research to accelerate dystrophin gene therapy commercialization.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/dystrophin-gene-therapy-market?kb
FDA Approvals
The FDA expanded approval of Elevidys (delandistrogene moxeparvovec-rokl) in 2024 for ambulatory and non-ambulatory DMD patients aged 4 and older with confirmed mutations in the DMD gene, becoming the first approved gene therapy addressing the root cause of DMD.
Elevidys approval was based on clinical trial data demonstrating sustained stabilization of motor function and muscle health over multiple years.
Givinostat, a histone deacetylase inhibitor, was approved to treat inflammation in DMD patients, supporting combination therapy strategies
Drugs Related to Dystrophin Gene Therapy
Approved and experimental drugs include exon-skipping therapies (eteplirsen, golodirsen, casimersen), HDAC inhibitors (givinostat), and gene therapies (Elevidys, RGX-202) aimed at restoring functional dystrophin protein in muscle cells.
Research into combination and next-generation gene therapies is active to enhance efficacy, durability, and patient eligibility.
Forecast Growth Projected:
The Global Dystrophin Gene Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the Dystrophin Gene Therapy Market:
Sarepta Therapeutics, Inc., and NS Pharma, Inc.
Dystrophin Gene Therapy Market Emerging Players
The major players in the dystrophin gene therapy market are REGENXBIO Inc., Solid Biosciences Inc., PepGen Inc., and Avidity Biosciences, among others
Segment Covered in the Dystrophin Gene Therapy Market:
By Therapeutic Approach: (Exon-Skipping, AAV Gene Therapy)
By Therapy: (Elevidys, Exondys 51, Amondys 45, Viltepso, Vyondys 53)
Get Customization in the report as per your requierments: https://datamintelligence.com/customize/dystrophin-gene-therapy-market?kb
Latest News & Research Developments
Genethon reported positive two-year efficacy results from its low-dose micro-dystrophin gene therapy (GNT0004) clinical trial showing significant motor function gains and reduced muscle damage biomarkers in DMD patients.
Clinical trials and real-world evidence increasingly show gene therapy's potential to slow disease progression in DMD, with ongoing Phase 3 pivotal studies underway.
Research continues into optimizing vector delivery, dosing, and patient selection to enhance therapeutic outcomes and reduce immune responses
Regional Analysis:
The global Dystrophin Gene Therapy Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Dystrophin Gene Therapy Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of Dystrophin Gene Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of Dystrophin Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=dystrophin-gene-therapy-market?kb
Latest M&A
In late 2024, Novartis acquired Kate Therapeutics, a biotech focused on AAV gene therapies including microdystrophin gene therapies for Duchenne muscular dystrophy (DMD), bolstering its neuroscience portfolio and rare disease pipeline.
Other notable biotech firms working on dystrophin gene therapy or microdystrophin constructs, such as Solid Biosciences, are consolidating assets and technologies to accelerate clinical development.
Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/dystrophin-gene-therapy-market?kb
Latest News & Research Developments
Genethon reported positive two-year efficacy results from its low-dose micro-dystrophin gene therapy (GNT0004) clinical trial showing significant motor function gains and reduced muscle damage biomarkers in DMD patients.
Clinical trials and real-world evidence increasingly show gene therapy's potential to slow disease progression in DMD, with ongoing Phase 3 pivotal studies underway.
Research continues into optimizing vector delivery, dosing, and patient selection to enhance therapeutic outcomes and reduce immune responses.
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dystrophin Gene Therapy Market to hit US$ 12.00 billion by 2033: Clinical Developments, Next Big Thing in Genetic Medicine here
News-ID: 4264242 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Hyperbaric Oxygen Therapy Devices Market Anticipated to Expand with Increasing A …
The Global Hyperbaric Oxygen Therapy Devices Market was valued at approximately USD 3.4 billion in 2023 and is expected to grow at a CAGR of 7.5% during the forecast period 2024-2032, reaching around USD 6.4 billion by 2032.
This growth is driven by increasing prevalence of chronic and acute wounds, rising awareness and acceptance of hyperbaric oxygen therapy, advancements in device technology, and expanding healthcare infrastructure. Growing medical tourism and the…
North America Flexible Packaging Market is to reach USD 63.69 billion by 2033- D …
The North America Flexible Packaging Market was valued at USD 48.21 billion in 2024, projected to reach USD 63.69 billion by 2033, growing at a CAGR of 3.02%..The North America Flexible Packaging Market is experiencing growth driven by increasing demand for lightweight, sustainable, and cost-efficient packaging solutions. Expanding applications across the food, beverage, and pharmaceutical industries, along with advancements in recyclable materials and consumer preference for convenience, are supporting consistent…
Algae-Based Wastewater Treatment Market Demand & Growth 2025 | Environmental Sol …
Global Algae-Based Wastewater Treatment Market reached US$ 2.65 billion in 2024 and is expected to reach US$ 4.19 billion by 2032, growing with a CAGR of 5.89% during the forecast period 2025-2032, according to DataM Intelligence report.
The Algae-Based Wastewater Treatment Market in Asia-Pacific showed steady growth, rising from $0.81 billion in 2022 to $0.84 billion in 2023.
United States: Recent Industry Developments
✅ October 2025: PhycoTech launched a pilot algae wastewater treatment…
Healthcare Data Interoperability Market Growth & Breakthroughs 2025 | Top 5 Comp …
DataM Intelligence has released its latest report on the "Healthcare Data Interoperability Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
